These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 23283428)

  • 1. Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over ("n-of-1") exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson's disease patients.
    Tison F; Nègre-Pagès L; Meissner WG; Dupouy S; Li Q; Thiolat ML; Thiollier T; Galitzky M; Ory-Magne F; Milhet A; Marquine L; Spampinato U; Rascol O; Bezard E
    Parkinsonism Relat Disord; 2013 Apr; 19(4):416-21. PubMed ID: 23283428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease.
    Wong KK; Alty JE; Goy AG; Raghav S; Reutens DC; Kempster PA
    Mov Disord; 2011 Jul; 26(8):1552-5. PubMed ID: 21538524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.
    Berg D; Godau J; Trenkwalder C; Eggert K; Csoti I; Storch A; Huber H; Morelli-Canelo M; Stamelou M; Ries V; Wolz M; Schneider C; Di Paolo T; Gasparini F; Hariry S; Vandemeulebroecke M; Abi-Saab W; Cooke K; Johns D; Gomez-Mancilla B
    Mov Disord; 2011 Jun; 26(7):1243-50. PubMed ID: 21484867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease.
    Kobylecki C; Burn DJ; Kass-Iliyya L; Kellett MW; Crossman AR; Silverdale MA
    Parkinsonism Relat Disord; 2014 Apr; 20(4):452-5. PubMed ID: 24521874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.
    Fox SH; Metman LV; Nutt JG; Brodsky M; Factor SA; Lang AE; Pope LE; Knowles N; Siffert J
    Mov Disord; 2017 Jun; 32(6):893-903. PubMed ID: 28370447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial.
    Rascol O; Bronzova J; Hauser RA; Lang AE; Sampaio C; Theeuwes A; van de Witte SV
    Parkinsonism Relat Disord; 2012 May; 18(4):370-6. PubMed ID: 22316635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.
    Stathis P; Konitsiotis S; Tagaris G; Peterson D;
    Mov Disord; 2011 Feb; 26(2):264-70. PubMed ID: 21412833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
    Pahwa R; Tanner CM; Hauser RA; Sethi K; Isaacson S; Truong D; Struck L; Ruby AE; McClure NL; Went GT; Stempien MJ
    Mov Disord; 2015 May; 30(6):788-95. PubMed ID: 25650051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
    Oertel W; Eggert K; Pahwa R; Tanner CM; Hauser RA; Trenkwalder C; Ehret R; Azulay JP; Isaacson S; Felt L; Stempien MJ
    Mov Disord; 2017 Dec; 32(12):1701-1709. PubMed ID: 28833562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease.
    Fox S; Silverdale M; Kellett M; Davies R; Steiger M; Fletcher N; Crossman A; Brotchie J
    Mov Disord; 2004 May; 19(5):554-60. PubMed ID: 15133820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial.
    Nutt JG; Carter JH; Carlson NE
    Arch Neurol; 2007 Mar; 64(3):319-23. PubMed ID: 17353373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of simvastatin on L-DOPA-induced abnormal involuntary movements of hemiparkinsonian rats.
    Wang T; Cao X; Zhang T; Shi Q; Chen Z; Tang B
    Neurol Sci; 2015 Aug; 36(8):1397-402. PubMed ID: 25787808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease.
    Watts RL; Lyons KE; Pahwa R; Sethi K; Stern M; Hauser RA; Olanow W; Gray AM; Adams B; Earl NL;
    Mov Disord; 2010 May; 25(7):858-66. PubMed ID: 20461803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.
    Ory-Magne F; Corvol JC; Azulay JP; Bonnet AM; Brefel-Courbon C; Damier P; Dellapina E; Destée A; Durif F; Galitzky M; Lebouvier T; Meissner W; Thalamas C; Tison F; Salis A; Sommet A; Viallet F; Vidailhet M; Rascol O;
    Neurology; 2014 Jan; 82(4):300-7. PubMed ID: 24371304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.
    Trenkwalder C; Berg D; Rascol O; Eggert K; Ceballos-Baumann A; Corvol JC; Storch A; Zhang L; Azulay JP; Broussolle E; Defebvre L; Geny C; Gostkowski M; Stocchi F; Tranchant C; Derkinderen P; Durif F; Espay AJ; Feigin A; Houeto JL; Schwarz J; Di Paolo T; Feuerbach D; Hockey HU; Jaeger J; Jakab A; Johns D; Linazasoro G; Maruff P; Rozenberg I; Sovago J; Weiss M; Gomez-Mancilla B
    Mov Disord; 2016 Jul; 31(7):1049-54. PubMed ID: 26990766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
    Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt MH; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
    Mov Disord; 2014 Sep; 29(10):1273-80. PubMed ID: 25044402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations.
    Hauser RA; Shulman LM; Trugman JM; Roberts JW; Mori A; Ballerini R; Sussman NM;
    Mov Disord; 2008 Nov; 23(15):2177-85. PubMed ID: 18831530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.